<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">JRA</journal-id>
<journal-id journal-id-type="hwp">spjra</journal-id>
<journal-id journal-id-type="nlm-ta">J Renin Angiotensin Aldosterone Syst</journal-id>
<journal-title>Journal of the Renin-Angiotensin-Aldosterone System</journal-title>
<issn pub-type="ppub">1470-3203</issn>
<issn pub-type="epub">1752-8976</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/1470320311430989</article-id>
<article-id pub-id-type="publisher-id">10.1177_1470320311430989</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Articles</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Gene polymorphisms of angiotensin-converting enzyme and angiotensin II Type 1 receptor among chronic kidney disease patients in a Chinese population</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name><surname>Su</surname><given-names>Sui-Lung</given-names></name>
<xref ref-type="aff" rid="aff1-1470320311430989">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Lu</surname><given-names>Kuo-Cheng</given-names></name>
<xref ref-type="aff" rid="aff2-1470320311430989">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Lin</surname><given-names>Yuh-Feng</given-names></name>
<xref ref-type="aff" rid="aff3-1470320311430989">3</xref>
<xref ref-type="aff" rid="aff4-1470320311430989">4</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Hsu</surname><given-names>Yu-Juei</given-names></name>
<xref ref-type="aff" rid="aff4-1470320311430989">4</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Lee</surname><given-names>Pong-Ying</given-names></name>
<xref ref-type="aff" rid="aff1-1470320311430989">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Yang</surname><given-names>Hsin-Yi</given-names></name>
<xref ref-type="aff" rid="aff5-1470320311430989">5</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Kao</surname><given-names>Sen-Yeong</given-names></name>
<xref ref-type="aff" rid="aff1-1470320311430989">1</xref>
</contrib>
</contrib-group>
<aff id="aff1-1470320311430989"><label>1</label>School of Public Health, National Defense Medical Center, Taipei, Taiwan, ROC</aff>
<aff id="aff2-1470320311430989"><label>2</label>Department of Internal Medicine, Cardinal Tien Hospital, School of Medicine, Fu Jen Catholic University, Taipei, Taiwan, ROC</aff>
<aff id="aff3-1470320311430989"><label>3</label>Department of Internal Medicine, Division of Nephrology, Shuang Ho Hospital, Taipei Medical University, Taipei, Taiwan, ROC</aff>
<aff id="aff4-1470320311430989"><label>4</label>Division of Nephrology, Department of Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan, ROC</aff>
<aff id="aff5-1470320311430989"><label>5</label>Graduate Institute of Life Sciences, National Defense Medical Center, Taipei, Taiwan, ROC</aff>
<author-notes>
<corresp id="corresp1-1470320311430989">Sui-Lung Su, School of Public Health, National Defense Medical Center, 161 Min-Chun E. Rd, Sec. 6, Nei-Hu, Taipei 114, Taiwan, ROC. Email: <email>a131419@gmail.com</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>3</month>
<year>2012</year>
</pub-date>
<volume>13</volume>
<issue>1</issue>
<fpage>148</fpage>
<lpage>154</lpage>
<permissions>
<copyright-statement>© SAGE Publications 2011</copyright-statement>
<copyright-year>2011</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<p>Chronic kidney disease (CKD) is highly prevalent in Taiwan and an increasing number of patients are affected, with a high risk of progression to end-stage renal disease and huge medical expenses. It has been predicted that the presence of hypertension increases with decreasing renal function due to a decrease in sodium excretion and activation of the renin–angiotensin system (RAS). The aim of this study was to investigate the influence of genetic variants of the RAS gene on CKD.</p>
<p>We performed a case control association study and genotyped 135 CKD patients and 270 healthy controls among Han Chinese in Taiwan. All subjects were genotyped for angiotensinogen (<italic>AGT</italic>-M235T, T174M, A-20C), angiotensin-I converting enzyme (<italic>ACE</italic>-A2350G) and angiotensin II type 1 receptor (<italic>AGTR1</italic>-A1166C, C573T, C-521T) polymorphisms of RAS genes by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) analysis. Significant associations were observed in <italic>ACE</italic>-A2350G and <italic>AGTR1</italic>-C573T polymorphism between CKD patients and controls. In regard to <italic>ACE</italic>-A2350G, compared with the AA genotype the GG genotype protected against CKD (adjusted odds ratio [OR] = 0.34; <italic>p</italic> = 0.01). In regard to <italic>AGTR1</italic>-C573T, the CT genotype was a risk for CKD compared with the CC genotype (adjusted OR = 1.82; <italic>p</italic> = 0.03). We conclude that <italic>ACE</italic>-A2350G and <italic>AGTR1</italic>-C573T polymorphisms are likely candidate determinants of CKD.</p>
</abstract>
<kwd-group>
<kwd>Chronic kidney disease (CKD)</kwd>
<kwd>angiotensinogen (AGT)</kwd>
<kwd>angiotensin-I converting enzyme (ACE)</kwd>
<kwd>angiotensin II type 1 receptor (AGTR1)</kwd>
<kwd>single nucleotide polymorphism (SNP)</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="section1-1470320311430989" sec-type="intro">
<title>Introduction</title>
<p>Taiwan has the third highest incidence and the highest prevalence of end-stage renal disease (ESRD) in the world.<sup><xref ref-type="bibr" rid="bibr1-1470320311430989">1</xref></sup> Dialysis patients constitute only 0.15% of the general population, but the cost of outpatient dialysis accounts for 7–8% of the total medical expenses of Taiwan’s National Health Insurance.<sup><xref ref-type="bibr" rid="bibr2-1470320311430989">2</xref></sup> In addition to ESRD, chronic kidney disease (CKD) is highly prevalent in Taiwan and contributes to an increased disease burden in this population. The prevalence rate of CKD is 11.9% in the general population aged over 20 years, but according to one large health examination study, it may reach 37.2% among the elderly.<sup><xref ref-type="bibr" rid="bibr3-1470320311430989">3</xref></sup> The impact of CKD on public health is worsening with increasing co-morbidity, mortality and medical expenses.<sup><xref ref-type="bibr" rid="bibr4-1470320311430989">4</xref></sup></p>
<p>Chronic kidney disease is a multifactorial disorder; its risk factors may include diabetes, hypertension, obesity and genetic factors.<sup><xref ref-type="bibr" rid="bibr5-1470320311430989">5</xref></sup> Genetic factors linked to early signs of renal disease, particularly increased urinary albumin excretion and hypertension, might be related to the progression of CKD, as these also emerge as pathophysiological factors in the deterioration of renal function. CKD displays familial clustering that may be explained by the dual effects of genetic susceptibility and environmental exposure.<sup><xref ref-type="bibr" rid="bibr6-1470320311430989">6</xref>,<xref ref-type="bibr" rid="bibr7-1470320311430989">7</xref></sup></p>
<p>The renin–angiotensin system (RAS) is a multifunctional system. A number of genetic variations involving components of the RAS have clinical or physiological impacts. Among the candidate genes of the RAS, the <italic>ACE, AGT</italic> and <italic>AGTR1</italic> genes seem to be particularly biologically and clinically relevant to renal disease. The genetic polymorphisms of these key components of the RAS provide a basis for studying the relationship between genetic variants and the development of vascular and/or renal damage in individual subjects.<sup><xref ref-type="bibr" rid="bibr8-1470320311430989">8</xref>–<xref ref-type="bibr" rid="bibr10-1470320311430989">10</xref></sup> The involvement of RAS gene polymorphisms in the pathogenesis of kidney disease has been extensively studied in various populations.<sup><xref ref-type="bibr" rid="bibr11-1470320311430989">11</xref>–<xref ref-type="bibr" rid="bibr15-1470320311430989">15</xref></sup> However, studies of RAS gene polymorphisms in CKD patients in Taiwan’s population are scanty. Studying RAS gene polymorphisms can yield knowledge about a patient’s disease progression and help in the design of better treatment options. In the present study, we examined the association of the <italic>ACE, AGT</italic> (-M235T, T174M and A-20C) and <italic>AGTR1</italic> (-A1166C, C573T and C-521T) gene polymorphisms with CKD susceptibility among Han Chinese in Taiwan.</p>
</sec>
<sec id="section2-1470320311430989" sec-type="materials|methods">
<title>Materials and methods</title>
<sec id="section3-1470320311430989">
<title>Patients and healthy controls</title>
<p>This case control study included 135 patients with stages 3–5 CKD receiving nephrology care at Cardinal Tien Hospital, Taipei, Taiwan. Our patients included diabetic nephropathy (<italic>n</italic> = 68), glomerulonephritis (<italic>n</italic> = 44) and others (<italic>n</italic> = 23). Renal function was calculated using the four-variable formula of the Modification of Diet in Renal Diseases (MDRD) Study for estimation of glomerular filtration rate (GFR) (GFR, ml/min/1.73 m<sup>2</sup> = 186.3 × [serum creatinine, mg/dl]<sup>−1.154</sup> × age<sup>−0.203</sup> × [0.742 if female or 1.212 if black]).<sup><xref ref-type="bibr" rid="bibr16-1470320311430989">16</xref></sup> The CKD classifications defined by the US National Kidney Foundation in 2002 were modified for the present study.<sup><xref ref-type="bibr" rid="bibr17-1470320311430989">17</xref></sup> For each patient, the estimated glomerular filtration rate (eGFR) was calculated by MDRD and then the patient was classified as having CKD stage 1–5. An eGFR of 30–59, 15–29 and &lt;15 ml/min/1.73 m<sup>2</sup> was defined as CKD stage 3, 4, and 5, respectively; 61 patients (45.2%) were assessed as stage 3, while clinical stages 4 and 5 were diagnosed in 44 (32.6%) and 30 (22.2%) patients, respectively. The 270 healthy control subjects were age- and sex-matched. The control subjects had an eGFR of ≥60 ml/min/1.73 m<sup>2</sup> and no proteinuria. They were recruited from the Center of Physical Examination at Cardinal Tien Hospital, and clinical variables were collected from medical records. Potential control subjects with hypertension or taking medication for any related diseases were excluded from the study. The ethics review committee of Cardinal Tien Hospital approved the study, and written informed consent was obtained from all participants.</p>
</sec>
<sec id="section4-1470320311430989">
<title>Genotyping</title>
<p>Five millilitres of blood was obtained from each individual, and DNA was isolated from peripheral leukocytes using standard procedures with proteinase K (Invitrogen, Carlsbad, CA, USA) digestion and phenol/chloroform extraction.<sup><xref ref-type="bibr" rid="bibr18-1470320311430989">18</xref></sup> The seven polymorphisms (<italic>AGT</italic>-M235T, T174M, A-20C, <italic>ACE</italic>-A2350G and <italic>AGTR1</italic>-A1166C, C573T and C-521T) were screened by thermocycler PCR system 9700 (GeneAmp; Applied Biosystems, CA, USA), followed by the restriction fragment length polymorphism (RFLP) technique. A PCR assay was performed with 10× buffer, 1.5 mM MgCl<sub>2</sub> and 0.2 mM each of dNTP and 1 U Taq DNA polymerase. PCR-grade water was added to a final volume of 50 µl. Digested products were run on agarose gels, stained with ethidium bromide and scored by UV visualisation. Details of the primers, cyclic conditions, restriction enzymes and genotype configurations are provided in <xref ref-type="table" rid="table1-1470320311430989">Table 1</xref>.</p>
<table-wrap id="table1-1470320311430989" position="float">
<label>Table1.</label>
<caption>
<p>SNPs in RAS genes, their primer sequences, PCR conditions and restriction enzyme with product sizes</p>
</caption>
<graphic alternate-form-of="table1-1470320311430989" xlink:href="10.1177_1470320311430989-table1.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup>
<thead>
<tr>
<th align="left">SNP</th>
<th align="left">rs ID</th>
<th align="left">Primer sequence (5’-3’)</th>
<th align="left">Cycling conditions</th>
<th align="left">Product size; restriction enzyme; products after digestion</th>
</tr>
</thead>
<tbody>
<tr>
<td><italic>AGT</italic>-M235T</td>
<td>699</td>
<td>F:GAGACGCCTTGAAG TAACTG</td>
<td>I 94°C 3’, D 94°C 30”, A 65°C 30”,</td>
<td>164 bp;</td>
</tr>
<tr>
<td/>
<td/>
<td>R: AACCAAAGATGTTCTGA ACTGA</td>
<td>E 72°C 30”, 35 cy, FE 72°C 5’</td>
<td>Tth111I; 139+25 bp</td>
</tr>
<tr>
<td><italic>AGT</italic>-T174M</td>
<td>4762</td>
<td>F:TGGCACCCTGGCCTCT CTCTATCT</td>
<td>I 94°C 3’, D 94°C 30”, A 60°C 30”,</td>
<td>351 bp;</td>
</tr>
<tr>
<td/>
<td/>
<td>R:CAGCCTGCATGAACCTGT CAATCT</td>
<td>E 72°C 30”, 35 cy, FE 72°C 5’</td>
<td>Nco I; 200+151 bp</td>
</tr>
<tr>
<td><italic>AGT</italic>-A-20C</td>
<td>5050</td>
<td>F:AGTGTCGCTTGGCATCTGT</td>
<td>I 94°C 3’, D 94°C 30”, A 59°C 30”,</td>
<td>208 bp;</td>
</tr>
<tr>
<td/>
<td/>
<td>R:GTCTTATGAGAGGGGA GAGAGGTTTT</td>
<td>E 72°C 30”, 30 cy, FE 72°C 5’</td>
<td>Eco0109I; 132+76 bp</td>
</tr>
<tr>
<td><italic>ACE</italic>-A2350G</td>
<td>4343</td>
<td>F:CGCCAATTTTATTCCAGCTC</td>
<td>I 95°C 5’, D 95°C 30”, A 58°C 30”,</td>
<td>199 bp;</td>
</tr>
<tr>
<td/>
<td/>
<td>R:TCGGGTAAAACTGGAGGATG</td>
<td>E 72°C 30”, 35 cy, FE 72°C 10’</td>
<td>BtsCI; 117+82 bp</td>
</tr>
<tr>
<td><italic>AGTR1</italic>-A1166C</td>
<td>5186</td>
<td>F:TCATTCTATGTGCTGGA GATGG</td>
<td>I 95°C 5’, D 95°C 30”, A 52°C 30”,</td>
<td>350 bp;</td>
</tr>
<tr>
<td/>
<td/>
<td>R:TGGGGGAAGTGGGTAAGAGT</td>
<td>E 72°C 30”, 35 cy, FE 72°C 5’</td>
<td>DdeI; 211+139 bp</td>
</tr>
<tr>
<td><italic>AGTR1</italic>-C573T</td>
<td>5182</td>
<td>F:GGTGAGCACTACCTGACTAGC</td>
<td>I 95°C 5’, D 95°C 30”, A 52°C 30”,</td>
<td>187 bp;</td>
</tr>
<tr>
<td/>
<td/>
<td>R:CCTAGGTCACAGTGACGTGG</td>
<td>E 72°C 30”, 35 cy, FE 72°C 5’</td>
<td>Hpy188III; 138+49 bp</td>
</tr>
<tr>
<td><italic>AGTR1</italic>-C-521T</td>
<td>1492078</td>
<td>F:CGTGATGTCTTTATCTGGTTTTG</td>
<td>I 95°C 5’, D 95°C 30”, A 62°C 30”,</td>
<td>271 bp;</td>
</tr>
<tr>
<td/>
<td/>
<td>R:CGAACTTTGGTAATACAGT TGTGG</td>
<td>E 72°C 30”, 30 cy, FE 72°C 5’</td>
<td>SspI; 145+126 bp</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-1470320311430989">
<p>SNP: single nucleotide polymorphism, F: forward, R: reverse, I: initial denaturation, °C: degree Celsius, D: denaturation, A: annealing, E: extension, cy: cycles, FE: final extension.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="section5-1470320311430989">
<title>Statistical analysis</title>
<p>For this case control association study, demographic and clinical data between groups were compared using Student’s <italic>t</italic>-test. The allele and genotype frequencies of control and patient groups were compared using χ<sup>2</sup> statistics or Fisher’s exact test when the expected count was less than five in &gt;33% of the input cells of the contingency table. The odds ratios (ORs) and corresponding 95% confidence intervals (CIs) for assessing the effect of genotype distribution and allele frequencies on CKD were calculated by logistic regression analysis with adjustment for relevant significant variables. <italic>P</italic> &lt; 0.05 was considered statistically significant. Data were analysed using SPSS statistical software 17.0 (SPSS Inc., Chicago, IL, USA).</p>
</sec>
</sec>
<sec id="section6-1470320311430989" sec-type="results">
<title>Results</title>
<sec id="section7-1470320311430989">
<title>Basic characteristics of the study population</title>
<p>Demographic and clinical characteristics of the subjects are presented in <xref ref-type="table" rid="table2-1470320311430989">Table 2</xref>. There was no significant difference in gender, age and diastolic blood pressure between the two groups. Significant differences in other variables were observed between CKD individuals and controls (<italic>p</italic> &lt; 0.05).</p>
<table-wrap id="table2-1470320311430989" position="float">
<label>Table 2.</label>
<caption>
<p>Characteristics of subjects with CKD and control subjects</p>
</caption>
<graphic alternate-form-of="table2-1470320311430989" xlink:href="10.1177_1470320311430989-table2.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th/>
<th align="left">CKD <italic>n</italic> = 135</th>
<th align="left">Control group <italic>n</italic> = 270</th>
<th align="left"><italic>p</italic>-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Male (%)</td>
<td>74 (54.8)</td>
<td>148 (54.8)</td>
<td>&gt; 0.05</td>
</tr>
<tr>
<td>Age (years)</td>
<td>71.4 ± 10.2</td>
<td>73.6 ± 8.1</td>
<td>&gt; 0.05</td>
</tr>
<tr>
<td>Body mass index (kg/m<sup>2</sup>)</td>
<td>25.6 ± 4.0</td>
<td>24.2 ± 3.2</td>
<td>&lt; 0.05</td>
</tr>
<tr>
<td colspan="4">Causes of CKD</td>
</tr>
<tr>
<td> Diabetic nephropathy (%)</td>
<td>68 (50)</td>
<td>–</td>
<td/>
</tr>
<tr>
<td> Glomerulonephritis (%)</td>
<td>44 (33)</td>
<td>–</td>
<td/>
</tr>
<tr>
<td> Others (%)</td>
<td>23 (17)</td>
<td>–</td>
<td/>
</tr>
<tr>
<td>Current or former smoker (%)</td>
<td>41 (34)</td>
<td>52 (18)</td>
<td>&lt; 0.05</td>
</tr>
<tr>
<td>Systolic blood pressure (mmHg)</td>
<td>135.2 ± 16.7</td>
<td>128.6 ± 14.6</td>
<td>&lt; 0.05</td>
</tr>
<tr>
<td>Diastolic blood pressure (mmHg)</td>
<td>76.4 ± 11.4</td>
<td>75.1 ± 11.6</td>
<td>&gt; 0.05</td>
</tr>
<tr>
<td>Fasting plasma glucose (mol/l)</td>
<td>120.0 ± 42.4</td>
<td>96.4 ± 10.2</td>
<td>&lt; 0.05</td>
</tr>
<tr>
<td>GFR</td>
<td>29.7 ± 16.0</td>
<td>85.5 ± 17.0</td>
<td>&lt; 0.05</td>
</tr>
<tr>
<td>BUN</td>
<td>40.9 ± 24.7</td>
<td>16.5 ± 6.9</td>
<td>&lt; 0.05</td>
</tr>
<tr>
<td>Serum creatinine (µmol/l)</td>
<td>2.9 ± 2.1</td>
<td>0.9 ± 0.2</td>
<td>&lt; 0.05</td>
</tr>
<tr>
<td>Serum total cholesterol (µmol/l)</td>
<td>189.6 ± 45.4</td>
<td>135.8 ± 67.4</td>
<td>&lt; 0.05</td>
</tr>
<tr>
<td>Serum triglyceride (µmol/l)</td>
<td>155.2 ± 83.6</td>
<td>119.8 ± 59.3</td>
<td>&lt; 0.05</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn2-1470320311430989">
<p>Quantitative data are means ± SD. CKD: chronic kidney disease, GFR: glomerular filtration rate, BUN: blood urea nitrogen</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="section8-1470320311430989">
<title>Hardy–Weinberg equilibrium</title>
<p>The <italic>AGT</italic> gene (M235T, T174M, A-20C), <italic>ACE</italic> gene (A2350G), and <italic>AGTR1</italic> gene (A1166C, C573T, C-521T) genotype distributions were all compatible with the Hardy–Weinberg expectation in cases and controls (<italic>p</italic> &gt; 0.05). This indicates that the study subjects were representative in the study field.</p>
</sec>
<sec id="section9-1470320311430989">
<title>Analysis of RAS gene polymorphism</title>
<p>Distributions of genotype and allele frequencies were compared between patients and controls (<xref ref-type="table" rid="table3-1470320311430989">Table 3</xref>). There were no significant differences in genotypic and allelic frequencies in the <italic>AGT</italic> gene (M235T, T174M, A-20C) between CKD patients and controls (<italic>p</italic> &gt; 0.05). The genotypic distributions and allelic frequencies of the <italic>ACE</italic>-A2350G polymorphism were not significantly different between the CKD and control groups, but after adjustment for the effects of other significant covariates (age, BMI, gender and smoking status) the <italic>ACE</italic>-A2350G polymorphism was significant.</p>
<table-wrap id="table3-1470320311430989" position="float">
<label>Table 3.</label>
<caption>
<p>Genotype distributions and allele frequencies for the <italic>AGT</italic> and <italic>AGTR1</italic> genes in patients with CKD and control subjects</p>
</caption>
<graphic alternate-form-of="table3-1470320311430989" xlink:href="10.1177_1470320311430989-table3.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th align="left">Genotype</th>
<th align="left">Patients (<italic>n</italic> = 135)</th>
<th align="left">Control group (<italic>n</italic> = 270)</th>
<th align="left">Crude OR (95% CI)</th>
<th align="left"><italic>p</italic>- value</th>
<th align="left">Adjusted OR (95% CI)</th>
<th align="left"><italic>p</italic>- value</th>
</tr>
</thead>
<tbody>
<tr>
<td colspan="7"><italic>AGT</italic>-M235T</td>
</tr>
<tr>
<td> CC</td>
<td>95 (70%)</td>
<td>198 (73%)</td>
<td>1</td>
<td/>
<td>1</td>
<td/>
</tr>
<tr>
<td> CT</td>
<td>37 (27%)</td>
<td>68 (25%)</td>
<td>1.13 (0.71–1.81)</td>
<td>0.60</td>
<td>1.12 (0.63–1.98)</td>
<td>0.82</td>
</tr>
<tr>
<td> TT</td>
<td>3 (2%)</td>
<td>4 (1%)</td>
<td>1.56 (0.34–7.12)</td>
<td>0.56</td>
<td>1.65 (0.34–8.10)</td>
<td>0.39</td>
</tr>
<tr>
<td>  T-allele</td>
<td>43 (16%)</td>
<td>76 (14%)</td>
<td>1.15 (0.77–1.73)</td>
<td>0.49</td>
<td>1.15 (0.71–1.87)</td>
<td>0.57</td>
</tr>
<tr>
<td colspan="7"><italic>AGT</italic>-T174M</td>
</tr>
<tr>
<td> TT</td>
<td>114 (84%)</td>
<td>222 (83%)</td>
<td>1</td>
<td/>
<td>1</td>
<td/>
</tr>
<tr>
<td> TC</td>
<td>20 (15%)</td>
<td>44 (16%)</td>
<td>0.89 (0.50–1.57)</td>
<td>0.67</td>
<td>0.84 (0.41–1.70)</td>
<td>0.62</td>
</tr>
<tr>
<td> CC</td>
<td>1 (1%)</td>
<td>4 (1%)</td>
<td>0.49 (0.05–4.41)</td>
<td>0.52</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>  C-allele</td>
<td>22 (8%)</td>
<td>52 (10%)</td>
<td>0.83 (0.49–1.40)</td>
<td>0.49</td>
<td>0.75 (0.38–1.46)</td>
<td>0.40</td>
</tr>
<tr>
<td colspan="7"><italic>AGT</italic>-A-20C</td>
</tr>
<tr>
<td> AC</td>
<td>118 (87%)</td>
<td>230 (85%)</td>
<td>1</td>
<td/>
<td>1</td>
<td/>
</tr>
<tr>
<td> CC</td>
<td>17 (13%)</td>
<td>40 (15%)</td>
<td>0.83 (0.45–1.52)</td>
<td>0.55</td>
<td>0.60 (0.28–1.29)</td>
<td>0.19</td>
</tr>
<tr>
<td>  C-allele</td>
<td>22 (56%)</td>
<td>52 (57%)</td>
<td>1.19 (0.66–2.15)</td>
<td>0.56</td>
<td>1.61 (0.77–3.39)</td>
<td>0.20</td>
</tr>
<tr>
<td colspan="7"><italic>ACE</italic>-A2350G</td>
</tr>
<tr>
<td> AA</td>
<td>62 (46%)</td>
<td>118 (44%)</td>
<td>1</td>
<td/>
<td>1</td>
<td/>
</tr>
<tr>
<td> AG</td>
<td>56 (41%)</td>
<td>96 (36%)</td>
<td>1.11 (0.71–1.74)</td>
<td>0.65</td>
<td>0.83 (0.48–1.45)</td>
<td>0.52</td>
</tr>
<tr>
<td> GG</td>
<td>17 (13%)</td>
<td>56 (21%)</td>
<td>0.58 (0.31–1.08)</td>
<td>0.09</td>
<td>0.34 (0.15–0.78)</td>
<td>0.01</td>
</tr>
<tr>
<td>  G-allele</td>
<td>90 (33%)</td>
<td>208 (39%)</td>
<td>0.80 (0.59–1.08)</td>
<td>0.14</td>
<td>0.60 (0.40–0.88)</td>
<td>0.01</td>
</tr>
<tr>
<td colspan="7"><italic>AGTR1</italic>-A1166C</td>
</tr>
<tr>
<td> AA</td>
<td>119 (88%)</td>
<td>244 (90%)</td>
<td>1</td>
<td/>
<td>1</td>
<td/>
</tr>
<tr>
<td> AC</td>
<td>16 (12%)</td>
<td>26 (10%)</td>
<td>1.26 (0.65–2.44)</td>
<td>0.49</td>
<td>1.27 (0.58–2.75)</td>
<td>0.55</td>
</tr>
<tr>
<td>  C-allele</td>
<td>16 (6%)</td>
<td>26 (5%)</td>
<td>1.24 (0.67–2.36)</td>
<td>0.51</td>
<td>1.24 (0.59–2.62)</td>
<td>0.57</td>
</tr>
<tr>
<td colspan="7"><italic>AGTR1</italic>-C573T</td>
</tr>
<tr>
<td> CC</td>
<td>54 (40%)</td>
<td>139 (51%)</td>
<td>1</td>
<td/>
<td>1</td>
<td/>
</tr>
<tr>
<td> CT</td>
<td>75 (56%)</td>
<td>113 (42%)</td>
<td>1.71 (1.11–2.62)</td>
<td>0.01</td>
<td>1.82 (1.07–3.09)</td>
<td>0.03</td>
</tr>
<tr>
<td> TT</td>
<td>6 (4%)</td>
<td>18 (7%)</td>
<td>0.76 (0.32–2.28)</td>
<td>0.76</td>
<td>1.05 (0.37–3.00)</td>
<td>0.93</td>
</tr>
<tr>
<td>  T-allele</td>
<td>87 (32%)</td>
<td>149 (28%)</td>
<td>1.24 (0.91–1.71)</td>
<td>0.18</td>
<td>1.28 (0.88–1.89)</td>
<td>0.20</td>
</tr>
<tr>
<td colspan="7"><italic>AGTR1</italic>-C-521T</td>
</tr>
<tr>
<td> CC</td>
<td>85 (63%)</td>
<td>178 (66%)</td>
<td>1</td>
<td/>
<td>1</td>
<td/>
</tr>
<tr>
<td> CT</td>
<td>47 (35%)</td>
<td>86 (32%)</td>
<td>1.14 (0.74–1.78)</td>
<td>0.55</td>
<td>0.98 (0.57–1.69)</td>
<td>0.94</td>
</tr>
<tr>
<td> TT</td>
<td>3 (2%)</td>
<td>6 (2%)</td>
<td>1.05 (0.26–4.29)</td>
<td>0.95</td>
<td>1.16 (0.20–6.58)</td>
<td>0.82</td>
</tr>
<tr>
<td>  T-allele</td>
<td>53 (20%)</td>
<td>98 (18%)</td>
<td>1.09 (0.76–1.59)</td>
<td>0.62</td>
<td>0.99 (0.63–1.58)</td>
<td>0.99</td>
</tr>
</tbody>
</table>
</table-wrap>
<p>In <italic>ACE</italic>-A2350G, the GG genotype compared with the AA genotype protected against CKD (unadjusted OR = 0.58; 95% CI: 0.31–1.08; <italic>p</italic> = 0.09; adjusted OR = 0.34; 95% CI: 0.15–0.78; <italic>p</italic> = 0.01). The carriers of the G allele of the <italic>ACE</italic> polymorphism were more frequent in the patient group compared with the control group (<italic>p</italic> = 0.01). In addition, we analysed <italic>ACE</italic>-A2350G under dominant and recessive modes. <italic>ACE</italic>-A2350G in the recessive mode showed a significant difference (unadjusted OR = 0.55; 95% CI: 0.31–0.99; <italic>p</italic> = 0.04; adjusted OR = 0.38, 95% CI = 0.17–0.82; <italic>p</italic> = 0.01, data not shown in table) in CKD patients compared with the control group.</p>
<p>Significant associations were observed in the <italic>AGTR1</italic>-C573T polymorphism between CKD patients and controls. In <italic>AGTR1</italic>-C573T, possession of the CT genotype compared with the CC genotype was a risk factor for CKD (unadjusted OR = 1.71; 95% CI: 1.11–2.62; <italic>p</italic> = 0.01; adjusted OR = 1.82; 95% CI: 1.07–3.09; <italic>p</italic> = 0.03).</p>
<p>There were no significant differences in genotypic and allelic frequencies in the <italic>AGTR1</italic> gene (A1166C and C-521T) between CKD patients and controls (<italic>p</italic> &gt; 0.05).</p>
</sec>
<sec id="section10-1470320311430989">
<title>Haplotype analysis of <italic>AGT</italic> and <italic>AGTR1</italic></title>
<p>The haplotype analysis of <italic>AGT</italic> and <italic>AGTR1</italic> gene polymorphisms in CKD patients and control subjects is shown in <xref ref-type="table" rid="table4-1470320311430989">Table 4</xref>. Four major <italic>AGT</italic> and <italic>AGTR1</italic> haplotypes (frequency ≥ 5%) were observed in our study. No significant differences in their frequency were observed between cases and controls (<italic>p</italic> &gt; 0.05).</p>
<table-wrap id="table4-1470320311430989" position="float">
<label>Table 4.</label>
<caption>
<p>Haplotype frequencies in <italic>AGT</italic> and <italic>AGTR1</italic> between CKD patients and control subjects</p>
</caption>
<graphic alternate-form-of="table4-1470320311430989" xlink:href="10.1177_1470320311430989-table4.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th align="left" colspan="7">AGT</th>
</tr>
</thead>
<tbody>
<tr>
<th align="left">C803T</th>
<th align="left">T620C</th>
<th align="left">A-20C</th>
<th align="left">Freq. (cases)</th>
<th align="left">Freq. (controls)</th>
<th align="left">OR</th>
<th align="left"><italic>p</italic>-value</th>
</tr>
<tr>
<td>C</td>
<td>T</td>
<td>C</td>
<td>0.71</td>
<td>0.71</td>
<td>1.02</td>
<td>0.91</td>
</tr>
<tr>
<td>T</td>
<td>T</td>
<td>C</td>
<td>0.14</td>
<td>0.12</td>
<td>1.17</td>
<td>0.48</td>
</tr>
<tr>
<td>C</td>
<td>C</td>
<td>C</td>
<td>0.07</td>
<td>0.09</td>
<td>0.84</td>
<td>0.52</td>
</tr>
<tr>
<td>C</td>
<td>T</td>
<td>A</td>
<td>0.05</td>
<td>0.06</td>
<td>0.90</td>
<td>0.76</td>
</tr>
<tr>
<td colspan="7"><italic>AGTR1</italic></td>
</tr>
<tr>
<td>C573T</td>
<td>C-521T</td>
<td>A1166C</td>
<td>Freq. (cases)</td>
<td>Freq. (controls)</td>
<td>OR</td>
<td><italic>p</italic>-value</td>
</tr>
<tr>
<td>C</td>
<td>C</td>
<td>A</td>
<td>0.54</td>
<td>0.57</td>
<td>0.88</td>
<td>0.40</td>
</tr>
<tr>
<td>T</td>
<td>C</td>
<td>A</td>
<td>0.21</td>
<td>0.21</td>
<td>1.04</td>
<td>0.83</td>
</tr>
<tr>
<td>C</td>
<td>T</td>
<td>A</td>
<td>0.13</td>
<td>0.13</td>
<td>0.95</td>
<td>0.82</td>
</tr>
<tr>
<td>T</td>
<td>T</td>
<td>A</td>
<td>0.07</td>
<td>0.05</td>
<td>1.44</td>
<td>0.25</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn3-1470320311430989">
<p>OR: odds ratio</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
</sec>
<sec id="section11-1470320311430989" sec-type="discussion">
<title>Discussion</title>
<p>The rate of ESRD is projected to increase, with an associated impact on public health costs<sup><xref ref-type="bibr" rid="bibr5-1470320311430989">5</xref></sup>. However, there is limited information on the genetic determinants of this complex trait for patients in Taiwan. Many studies have concentrated only on single gene polymorphisms in candidate or modifier genes with respect to a single disease. Here, we attempted to explore RAS gene polymorphisms in CKD patients in Taiwan.</p>
<p>Polymorphisms in <italic>AGT</italic>, located on chromosome 1q42–q43, are associated with increased risk for renal progression and cardiovascular disease. Reported frequently in the literature, the M235T SNP is a methionine (Met) to threonine (Thr) amino acid substitution at codon 235. The Thr/Thr genotype is associated with increased risk for hypertension in the general population<sup><xref ref-type="bibr" rid="bibr19-1470320311430989">19</xref>,<xref ref-type="bibr" rid="bibr20-1470320311430989">20</xref></sup> and in kidney transplant patients with chronic allograft dysfunction. Several reports have investigated the relationship between <italic>AGT</italic> gene M235T polymorphism and the development and progression of renal failure in patients with different primary renal diseases. Some have reported an association of the T allele of this polymorphism with the development of chronic renal disease and renal failure.<sup><xref ref-type="bibr" rid="bibr13-1470320311430989">13</xref>,<xref ref-type="bibr" rid="bibr21-1470320311430989">21</xref>,<xref ref-type="bibr" rid="bibr22-1470320311430989">22</xref></sup> However, our study showed no significant association between CKD patients and this polymorphism compared with the control group. The failure to find an association could be attributed to the different races.<sup><xref ref-type="bibr" rid="bibr16-1470320311430989">16</xref>,<xref ref-type="bibr" rid="bibr17-1470320311430989">17</xref></sup></p>
<p><italic>AGT</italic>-T174M SNP is a Thr to Met amino acid substitution at exon 2. The Met/Met genotype is associated with higher levels of <italic>AGT</italic>. Vasků et al.<sup><xref ref-type="bibr" rid="bibr23-1470320311430989">23</xref></sup> demonstrated that <italic>AGT</italic>-T174M polymorphisms have significant statistical differences for hypertensive disease.<sup><xref ref-type="bibr" rid="bibr19-1470320311430989">19</xref></sup> <italic>AGT</italic>-A-20C, located in the promoter region between the TATA box and translation start site, will accelerate the rate of <italic>AGT</italic> transcription and thereby alter the plasma <italic>AGT</italic> level.<sup><xref ref-type="bibr" rid="bibr20-1470320311430989">20</xref></sup> Our study results demonstrated that the <italic>AGT</italic>-T174M and -A-20C polymorphisms have no significant association with CKD compared with the control group; this is consistent with previous reports that there were no differences in <italic>AGT</italic>-T174M and -A-20C SNP distributions between a systolic heart failure group and control group.<sup><xref ref-type="bibr" rid="bibr13-1470320311430989">13</xref></sup></p>
<p>The <italic>ACE</italic> gene, which is located on chromosome 17q23, contains some gene polymorphisms and candidate markers for hypertension and related diseases.<sup><xref ref-type="bibr" rid="bibr21-1470320311430989">21</xref></sup></p>
<p>Zhu et al. demonstrated that the G allele for the <italic>ACE</italic>-A2350G gene polymorphism is significantly associated with higher blood pressure and <italic>ACE</italic> concentration.<sup><xref ref-type="bibr" rid="bibr24-1470320311430989">24</xref></sup> In this study, we found an association between <italic>ACE-</italic>A2350G in a Taiwanese population when we adjusted the effects of other significant covariates (age, BMI, gender and smoking status). Compared with the AA genotype, the GG genotype protected against CKD. Carriers of the G allele of the <italic>ACE</italic> polymorphism were more frequent in the patient group compared with the control group. Our results are consistent with previous reports that the <italic>ACE</italic> 2350A allele is associated with significantly elevated hypertension risk among Han Chinese.<sup><xref ref-type="bibr" rid="bibr25-1470320311430989">25</xref>,<xref ref-type="bibr" rid="bibr26-1470320311430989">26</xref></sup></p>
<p>The <italic>AGTR1</italic> gene is located on chromosome 3q21–25 and is more than 55 kb long; additionally, it has been associated with risk of renal progression and cardiovascular disease.<sup><xref ref-type="bibr" rid="bibr23-1470320311430989">23</xref></sup> The <italic>AGTR1-</italic>A1166C polymorphism had been investigated in many studies in relation to blood pressure, and sometimes in relation to renal failure risk and other risk factors, producing a variety of results.<sup><xref ref-type="bibr" rid="bibr27-1470320311430989">27</xref>–<xref ref-type="bibr" rid="bibr31-1470320311430989">31</xref></sup> However, our study showed no difference between the CKD and control groups on the A1166C polymorphism. The <italic>AGTR1</italic>-C521T C polymorphism also did not differ greatly in frequency between the CKD and control groups. These discrepancies could be partly due to the fact that these studies analysed different populations worldwide and that the risk of renal failure and risk factor levels are multifactorial, including many environmental and genetic factors and their interactions.<sup><xref ref-type="bibr" rid="bibr32-1470320311430989">32</xref>,<xref ref-type="bibr" rid="bibr33-1470320311430989">33</xref></sup></p>
<p>In contrast, research on the <italic>AGTR1</italic>-C573T polymorphism has been reported in only a few articles and generally in relation to blood pressure.<sup><xref ref-type="bibr" rid="bibr34-1470320311430989">34</xref>,<xref ref-type="bibr" rid="bibr35-1470320311430989">35</xref></sup> However, significant associations were observed in the <italic>AGTR1</italic>-C573T polymorphism between CKD patients and controls. The <italic>AGTR1</italic>-C573T polymorphism does not change the sense of codon 191 (CTC→CTT), which codifies for leucine. This polymorphism could be responsible for alteration in AT1 receptor function. Alternatively, the presence of the 573T allele could be in linkage disequilibrium with other polymorphisms in the sequence of the AT1 receptor gene or with alterations in other genes located close to the 3q21–q25 region.</p>
<p>Our study has certain limitations. (1) The study was conducted with a limited sample size that might lead to lower statistical power. (2) There is no replication cohort and, due to the high rate of false positives in genetics, the findings could still be due to chance. (3) The study is also limited by lacking functional analysis (in vitro) of the polymorphism. (4) There are other important factors (e.g. genetic or environmental) that may have more impact than one particular polymorphism in causing chronic kidney disease.</p>
</sec>
<sec id="section12-1470320311430989" sec-type="conclusions">
<title>Conclusion</title>
<p>In conclusion, <italic>AGTR1</italic>-C573T and <italic>ACE</italic>-A2350G polymorphisms are likely candidate determinants of CKD. There was no association between <italic>AGT</italic> polymorphisms and susceptibility to CKD. Further studies are needed to assess <italic>AGTR1</italic>-C573T polymorphisms to determine whether or not this effect results from genotype-mediated receptor activation. The possibility that individuals with the G allele of the <italic>ACE</italic>-A2350G polymorphism have a lower risk of developing kidney damage should be explored for other kidney diseases.</p>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="financial-disclosure">
<p>This study was supported by grants from the National Science Council and National Defense Medical Center and Cardinal Tien Hospital, Taiwan, ROC (NSC99-2314-B-016-001, NSC99-2815-C-016-002-B, CTH-NC9805, CTH- NC10007).</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-1470320311430989">
<label>1.</label>
<citation citation-type="web">
<collab>US Renal Data System</collab>. <comment>Annual Data Report</comment>. <ext-link ext-link-type="uri" xlink:href="http://www.usrds.org/2010/pdf/v2_12.pdf">www.usrds.org/2010/pdf/v2_12.pdf</ext-link></citation>
</ref>
<ref id="bibr2-1470320311430989">
<label>2.</label>
<citation citation-type="gov">
<collab>National Health Insurance Annual Statistical Report</collab> <year>2003</year>. <comment>Department of Health. Taiwan: Executive Yuan, R.O.C.</comment> <year>2003</year>. <ext-link ext-link-type="uri" xlink:href="http://www.nhicb.gov.tw/Resource/webdata/Attach_8661_1_s92.pdf">www.nhicb.gov.tw/Resource/webdata/Attach_8661_1_s92.pdf</ext-link></citation>
</ref>
<ref id="bibr3-1470320311430989">
<label>3.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Wen</surname><given-names>CP</given-names></name>
<name><surname>Cheng</surname><given-names>TY</given-names></name>
<name><surname>Tsai</surname><given-names>MK</given-names></name>
<name><surname>Chang</surname><given-names>YC</given-names></name>
<name><surname>Chan</surname><given-names>HT</given-names></name>
<name><surname>Tsai</surname><given-names>SP</given-names></name><etal/>
</person-group>. <article-title>All-cause mortality attributable to chronic kidney disease: a prospective cohort study based on 462293 adults in Taiwan</article-title>. <source>Lancet</source> <year>2008</year>; <volume>371</volume>: <fpage>2173</fpage>–<lpage>2182</lpage>.</citation>
</ref>
<ref id="bibr4-1470320311430989">
<label>4.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Satko</surname><given-names>SG</given-names></name>
<name><surname>Sedor</surname><given-names>JR</given-names></name>
<name><surname>Iyengar</surname><given-names>SK</given-names></name>
<name><surname>Freedman</surname><given-names>BI</given-names></name>
</person-group>. <article-title>Familial clustering of chronic kidney disease</article-title> <source>Semin Dial</source> <year>2007</year>; <volume>20</volume>: <fpage>229</fpage>–<lpage>236</lpage>.</citation>
</ref>
<ref id="bibr5-1470320311430989">
<label>5.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hwang</surname><given-names>SJ</given-names></name>
<name><surname>Tsai</surname><given-names>JC</given-names></name>
<name><surname>Chen</surname><given-names>HC</given-names></name>
</person-group>. <article-title>Epidemiology, impact and preventive care of chronic kidney disease in Taiwan</article-title>. <source>Nephrology</source> <year>2010</year>; <volume>15</volume>: <fpage>3</fpage>–<lpage>9</lpage>.</citation>
</ref>
<ref id="bibr6-1470320311430989">
<label>6.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>McClellan</surname><given-names>WM</given-names></name>
<name><surname>Flanders</surname><given-names>WD</given-names></name>
</person-group>. <article-title>Risk factors for progressive chronic kidney disease</article-title>. <source>J Am Soc Nephrol</source> <year>2003</year>; <volume>14</volume>: <fpage>S65</fpage>–<lpage>S70</lpage>.</citation>
</ref>
<ref id="bibr7-1470320311430989">
<label>7.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Luttropp</surname><given-names>K</given-names></name>
<name><surname>Lindholm</surname><given-names>B</given-names></name>
<name><surname>Carrero</surname><given-names>JJ</given-names></name>
<name><surname>Glorieux</surname><given-names>G</given-names></name>
<name><surname>Schepers</surname><given-names>E</given-names></name>
<name><surname>Vanholderet</surname><given-names>R</given-names></name><etal/>
</person-group>. <article-title>Genetics/genomics in chronic kidney disease--towards personalized medicine?</article-title> <source>Semin Dial</source> <year>2009</year>; <volume>22</volume>: <fpage>417</fpage>–<lpage>422</lpage>.</citation>
</ref>
<ref id="bibr8-1470320311430989">
<label>8.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Crisan</surname><given-names>D</given-names></name>
<name><surname>Carr</surname><given-names>J</given-names></name>
</person-group>. <article-title>Angiotensin I-converting enzyme: genotype and disease associations</article-title>. <source>J Mol Diagn</source> <year>2000</year>; <volume>2</volume>: <fpage>105</fpage>–<lpage>115</lpage>.</citation>
</ref>
<ref id="bibr9-1470320311430989">
<label>9.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ortiz</surname><given-names>MA</given-names></name>
<name><surname>De Prado</surname><given-names>A</given-names></name>
<name><surname>Doñate</surname><given-names>T</given-names></name>
<name><surname>Gallart</surname><given-names>L</given-names></name>
<name><surname>Claramunt</surname><given-names>H</given-names></name>
<name><surname>Hernandez</surname><given-names>M</given-names></name><etal/>
</person-group>. <article-title>Angiotensin converting enzyme polymorphism gene and evolution of nephropathy to end stage renal disease</article-title>. <source>Nephrology</source> <year>2003</year>; <volume>8</volume>: <fpage>171</fpage>–<lpage>176</lpage>.</citation>
</ref>
<ref id="bibr10-1470320311430989">
<label>10.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Miller</surname><given-names>JA</given-names></name>
<name><surname>Scholey</surname><given-names>JW</given-names></name>
</person-group>. <article-title>The impact of renin-angiotensin system polymorphisms on physiological and pathophysiological processes in humans</article-title>. <source>Curr Opin Nephrol Hypertens</source> <year>2004</year>; <volume>13</volume>: <fpage>101</fpage>–<lpage>106</lpage>.</citation>
</ref>
<ref id="bibr11-1470320311430989">
<label>11.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Schmidt</surname><given-names>S</given-names></name>
<name><surname>Schöne</surname><given-names>N</given-names></name>
<name><surname>Ritz</surname><given-names>E</given-names></name>
</person-group>. <article-title>Association of ACE gene polymorphism and diabetic nephropathy? The Diabetic Nephropathy Study Group</article-title>. <source>Kidney Int</source> <year>1995</year>; <volume>47</volume>: <fpage>1176</fpage>–<lpage>1181</lpage>.</citation>
</ref>
<ref id="bibr12-1470320311430989">
<label>12.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Dudley</surname><given-names>CR</given-names></name>
<name><surname>Keavney</surname><given-names>B</given-names></name>
<name><surname>Stratton</surname><given-names>IM</given-names></name>
<name><surname>Turner</surname><given-names>RC</given-names></name>
<name><surname>Ratcliffe</surname><given-names>PJ</given-names></name>
</person-group>. <article-title>U.K. Prospective Diabetes Study. XV: Relationship of renin-angiotensin system gene polymorphisms with microalbuminuria in NIDDM</article-title>. <source>Kidney Int</source> <year>1995</year>; <volume>48</volume>: <fpage>1907</fpage>–<lpage>1911</lpage>.</citation>
</ref>
<ref id="bibr13-1470320311430989">
<label>13.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lovati</surname><given-names>E</given-names></name>
<name><surname>Richard</surname><given-names>A</given-names></name>
<name><surname>Frey</surname><given-names>BM</given-names></name>
<name><surname>Frey</surname><given-names>FJ</given-names></name>
<name><surname>Ferrari</surname><given-names>P</given-names></name>
</person-group>. <article-title>Genetic polymorphisms of the renin-angiotensin-aldosterone system in end-stage renal disease</article-title>. <source>Kidney Int</source> <year>2001</year>; <volume>60</volume>: <fpage>46</fpage>–<lpage>54</lpage>.</citation>
</ref>
<ref id="bibr14-1470320311430989">
<label>14.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Viswanathan</surname><given-names>V</given-names></name>
<name><surname>Zhu</surname><given-names>Y</given-names></name>
<name><surname>Bala</surname><given-names>K</given-names></name>
<name><surname>Dunn</surname><given-names>S</given-names></name>
<name><surname>Snehalatha</surname><given-names>C</given-names></name>
<name><surname>Ramachandran</surname><given-names>A</given-names></name><etal/>
</person-group>. <article-title>Association between ACE gene polymorphism and diabetic nephropathy in South Indian patients</article-title>. <source>JOP</source> <year>2001</year>; <volume>2</volume>: <fpage>83</fpage>–<lpage>87</lpage>.</citation>
</ref>
<ref id="bibr15-1470320311430989">
<label>15.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Prasad</surname><given-names>P</given-names></name>
<name><surname>Tiwari</surname><given-names>AK</given-names></name>
<name><surname>Kumar</surname><given-names>K</given-names></name>
<name><surname>Prasanna Kumar</surname><given-names>KM</given-names></name>
<name><surname>Ammini</surname><given-names>AC</given-names></name>
<name><surname>Gupta</surname><given-names>A</given-names></name><etal/>
</person-group>. <article-title>Chronic renal insufficiency among Asian Indians with type 2 diabetes: I. Role of RAAS gene polymorphisms</article-title>. <source>BMC Med Genet</source> <year>2006</year>; <volume>7</volume>: <fpage>42</fpage>.</citation>
</ref>
<ref id="bibr16-1470320311430989">
<label>16.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Levey</surname><given-names>A</given-names></name>
<name><surname>Greene</surname><given-names>T</given-names></name>
<name><surname>Kusek</surname><given-names>J</given-names></name>
<name><surname>Beck</surname><given-names>G</given-names></name>
</person-group>. <article-title>A simplified equation to predict glomerular filtration rate from serum creatinine</article-title>. <source>J Am Soc Nephrol</source> <year>2000</year>; <volume>11</volume>: <fpage>155A</fpage>.</citation>
</ref>
<ref id="bibr17-1470320311430989">
<label>17.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Levey</surname><given-names>AS</given-names></name>
<name><surname>Coresh</surname><given-names>J</given-names></name>
<name><surname>Balk</surname><given-names>E</given-names></name>
<name><surname>Kausz</surname><given-names>AT</given-names></name>
<name><surname>Levin</surname><given-names>A</given-names></name>
<name><surname>Steffes</surname><given-names>MW</given-names></name><etal/>
</person-group>. <article-title>National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification</article-title>. <source>Ann Intern Med</source> <year>2003</year>; <volume>139</volume>: <fpage>137</fpage>–<lpage>147</lpage>.</citation>
</ref>
<ref id="bibr18-1470320311430989">
<label>18.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Poncz</surname><given-names>M</given-names></name>
<name><surname>Solowiejczyk</surname><given-names>D</given-names></name>
<name><surname>Harpel</surname><given-names>B</given-names></name>
<name><surname>Mory</surname><given-names>Y</given-names></name>
<name><surname>Schwartz</surname><given-names>E</given-names></name>
<name><surname>Surrey</surname><given-names>S</given-names></name><etal/>
</person-group>. <article-title>Construction of human gene libraries from small amounts of peripheral blood</article-title>. <source>Hemoglobin</source> <year>1982</year>; <volume>6</volume>: <fpage>27</fpage>–<lpage>36</lpage>.</citation>
</ref>
<ref id="bibr19-1470320311430989">
<label>19.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Caulfield</surname><given-names>M</given-names></name>
<name><surname>Lavender</surname><given-names>P</given-names></name>
<name><surname>Farrall</surname><given-names>M</given-names></name>
<name><surname>Munroe</surname><given-names>P</given-names></name>
<name><surname>Lawson</surname><given-names>M</given-names></name>
<name><surname>Turner</surname><given-names>PC</given-names></name><etal/>
</person-group>. <article-title>Linkage of the angiotensinogen gene to essential hypertension</article-title>. <source>N Engl J Med</source> <year>1994</year>; <volume>330</volume>: <fpage>1629</fpage>–<lpage>1633</lpage>.</citation>
</ref>
<ref id="bibr20-1470320311430989">
<label>20.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Baudin</surname><given-names>B</given-names></name>
</person-group>. <article-title>Polymorphism in angiotensin II receptor genes and hypertension</article-title>. <source>Exp Physiol</source> <year>2005</year>; <volume>90</volume>: <fpage>277</fpage>–<lpage>282</lpage>.</citation>
</ref>
<ref id="bibr21-1470320311430989">
<label>21.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gumprecht</surname><given-names>J</given-names></name>
<name><surname>Zychma</surname><given-names>MJ</given-names></name>
<name><surname>Grzeszczak</surname><given-names>W</given-names></name>
<name><surname>Zukowska-Szczechowska</surname><given-names>E</given-names></name>
</person-group>. <article-title>Angiotensin I-converting enzyme gene insertion/deletion and angiotensinogen M235T polymorphisms: risk of chronic renal failure</article-title>. <source>Kidney Int</source> <year>2000</year>; <volume>58</volume>: <fpage>513</fpage>–<lpage>519</lpage>.</citation>
</ref>
<ref id="bibr22-1470320311430989">
<label>22.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rogus</surname><given-names>JJ</given-names></name>
<name><surname>Moczulski</surname><given-names>D</given-names></name>
<name><surname>Freire</surname><given-names>MB</given-names></name>
<name><surname>Yang</surname><given-names>Y</given-names></name>
<name><surname>Warram</surname><given-names>JH</given-names></name>
<name><surname>Krolewski</surname><given-names>AS</given-names></name><etal/>
</person-group>. <article-title>Diabetic nephropathy is associated with AGT polymorphism T235: results of a family-based study</article-title>. <source>Hypertension</source> <year>1998</year>; <volume>31</volume>: <fpage>627</fpage>–<lpage>631</lpage>.</citation>
</ref>
<ref id="bibr23-1470320311430989">
<label>23.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Vasků</surname><given-names>A</given-names></name>
<name><surname>Soucek</surname><given-names>M</given-names></name>
<name><surname>Tschöplová</surname><given-names>S</given-names></name>
<name><surname>Stejskalová</surname><given-names>A</given-names></name>
</person-group>. <article-title>An association of BMI with A (-6) G, M235T and T174M polymorphisms in angiotensinogen gene in essential hypertension</article-title>. <source>J Hum Hypertens</source> <year>2002</year>; <volume>16</volume>: <fpage>427</fpage>–<lpage>430</lpage>.</citation>
</ref>
<ref id="bibr24-1470320311430989">
<label>24.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Zhu</surname><given-names>X</given-names></name>
<name><surname>Bouzekri</surname><given-names>N</given-names></name>
<name><surname>Southam</surname><given-names>L</given-names></name>
<name><surname>Cooper</surname><given-names>RS</given-names></name>
<name><surname>Adeyemo</surname><given-names>A</given-names></name>
<name><surname>McKenzie</surname><given-names>CA</given-names></name><etal/>
</person-group>. <article-title>Linkage and association analysis of angiotensin I-converting enzyme (ACE)-gene polymorphisms with ACE concentration and blood pressure</article-title>. <source>Am J Hum Genet</source> <year>2001</year>; <volume>68</volume>: <fpage>1139</fpage>–<lpage>1148</lpage>.</citation>
</ref>
<ref id="bibr25-1470320311430989">
<label>25.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Frimat</surname><given-names>L</given-names></name>
<name><surname>Philippe</surname><given-names>C</given-names></name>
<name><surname>Maghakian</surname><given-names>MN</given-names></name>
<name><surname>Jonveaux</surname><given-names>P</given-names></name>
<name><surname>Hurault</surname><given-names>de</given-names></name>
<name><surname>Ligny</surname><given-names>B</given-names></name>
<name><surname>Guillemin</surname><given-names>F</given-names></name><etal/>
</person-group>. <article-title>Polymorphism of angiotensin converting enzyme, angiotensinogen, and angiotensin II type 1 receptor genes and end-stage renal failure in IgA nephropathy: IGARAS--Xa study of 274 men</article-title>. <source>J Am Soc Nephrol</source> <year>2000</year>; <volume>11</volume>: <fpage>2062</fpage>–<lpage>2067</lpage>.</citation>
</ref>
<ref id="bibr26-1470320311430989">
<label>26.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Tomino</surname><given-names>Y</given-names></name>
<name><surname>Makita</surname><given-names>Y</given-names></name>
<name><surname>Shike</surname><given-names>T</given-names></name>
<name><surname>Gohda</surname><given-names>T</given-names></name>
<name><surname>Haneda</surname><given-names>M</given-names></name>
<name><surname>Kikkawa</surname><given-names>R</given-names></name><etal/>
</person-group>. <article-title>Relationship between polymorphism in the angiotensinogen, angiotensin-converting enzyme or angiotensin II receptor and renal progression in Japanese NIDDM patients</article-title>. <source>Nephron</source> <year>2000</year>; <volume>82</volume>: <fpage>139</fpage>–<lpage>144</lpage>.</citation>
</ref>
<ref id="bibr27-1470320311430989">
<label>27.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Jeunemaitre</surname><given-names>X</given-names></name>
<name><surname>Soubrier</surname><given-names>F</given-names></name>
<name><surname>Kotelevtsev</surname><given-names>YV</given-names></name>
<name><surname>Lifton</surname><given-names>RP</given-names></name>
<name><surname>Williams</surname><given-names>CS</given-names></name>
<name><surname>Charru</surname><given-names>A</given-names></name><etal/>
</person-group>. <article-title>Molecular basis of human hypertension: role of angiotensinogen</article-title>. <source>Cell</source> <year>1992</year>; <volume>71</volume>: <fpage>169</fpage>–<lpage>180</lpage>.</citation>
</ref>
<ref id="bibr28-1470320311430989">
<label>28.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Chang</surname><given-names>SN</given-names></name>
<name><surname>Lin</surname><given-names>JW</given-names></name>
<name><surname>Juang</surname><given-names>JM</given-names></name>
<name><surname>Tsai</surname><given-names>CT</given-names></name>
<name><surname>Hwang</surname><given-names>JJ</given-names></name>
<name><surname>Chiang</surname><given-names>FT</given-names></name>
</person-group>. <article-title>Association between genetic polymorphisms in the renin-angiotensin system and systolic heart failure revised by a propensity score-based analysis</article-title>. <source>Cardiology</source> <year>2010</year>; <volume>116</volume>: <fpage>279</fpage>–<lpage>285</lpage>.</citation>
</ref>
<ref id="bibr29-1470320311430989">
<label>29.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Doria</surname><given-names>A</given-names></name>
<name><surname>Warram</surname><given-names>J</given-names></name>
<name><surname>Rich</surname><given-names>S</given-names></name>
<name><surname>Krolewski</surname><given-names>A</given-names></name>
</person-group>. <article-title>Angiotensin I-converting enzyme (ACE): estimation of DNA haplotypes in unrelated individuals using denaturing gradient gel blots</article-title>. <source>Hum Gene</source> <year>1994</year>; <volume>94</volume>: <fpage>117</fpage>–<lpage>123</lpage>.</citation>
</ref>
<ref id="bibr30-1470320311430989">
<label>30.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Niu</surname><given-names>W</given-names></name>
<name><surname>Qi</surname><given-names>Y</given-names></name>
<name><surname>Hou</surname><given-names>S</given-names></name>
<name><surname>Zhai</surname><given-names>X</given-names></name>
<name><surname>Zhou</surname><given-names>W</given-names></name>
<name><surname>Qiu</surname><given-names>C</given-names></name>
</person-group>. <article-title>Haplotype-based association of the renin-angiotensin-aldosterone system genes polymorphisms with essential hypertension among Han Chinese: the Fangshan study</article-title>. <source>J Hypertens</source> <year>2009</year>; <volume>27</volume>: <fpage>1384</fpage>–<lpage>1391</lpage>.</citation>
</ref>
<ref id="bibr31-1470320311430989">
<label>31.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Pan</surname><given-names>M</given-names></name>
<name><surname>Zhu</surname><given-names>JH</given-names></name>
<name><surname>Liu</surname><given-names>ZH</given-names></name>
<name><surname>Jiang</surname><given-names>WP</given-names></name>
<name><surname>Cui</surname><given-names>ZC</given-names></name>
<name><surname>Yu</surname><given-names>XH</given-names></name><etal/>
</person-group>. <article-title>Angiotensin-converting enzyme gene 2350 G/A polymorphism is associated with left ventricular hypertrophy but not essential hypertension</article-title>. <source>Hypertens Res</source> <year>2007</year>; <volume>30</volume>: <fpage>31</fpage>–<lpage>37</lpage>.</citation>
</ref>
<ref id="bibr32-1470320311430989">
<label>32.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Curnow</surname><given-names>KM</given-names></name>
<name><surname>Pascoe</surname><given-names>L</given-names></name>
<name><surname>White</surname><given-names>P</given-names></name>
</person-group>. <article-title>Genetic analysis of the human type-1 angiotensin II receptor</article-title>. <source>Mol Endocrinol</source> <year>1992</year>; <volume>6</volume>: <fpage>1113</fpage>–<lpage>1118</lpage>.</citation>
</ref>
<ref id="bibr33-1470320311430989">
<label>33.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Buraczynska</surname><given-names>M</given-names></name>
<name><surname>Ksiazek</surname><given-names>P</given-names></name>
<name><surname>Drop</surname><given-names>A</given-names></name>
<name><surname>Zaluska</surname><given-names>W</given-names></name>
<name><surname>Spasiewicz</surname><given-names>D</given-names></name>
<name><surname>Ksiazek</surname><given-names>A</given-names></name>
</person-group>. <article-title>Genetic polymorphisms of the renin- angiotensin system in end-stage renal disease</article-title>. <source>Nephrol Dial Transplant</source> <year>2006</year>; <volume>21</volume>: <fpage>979</fpage>–<lpage>983</lpage>.</citation>
</ref>
<ref id="bibr34-1470320311430989">
<label>34.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Buraczynska</surname><given-names>M</given-names></name>
<name><surname>Ksiazek</surname><given-names>P</given-names></name>
<name><surname>Zaluska</surname><given-names>W</given-names></name>
<name><surname>Spasiewicz</surname><given-names>D</given-names></name>
<name><surname>Nowicka</surname><given-names>T</given-names></name>
<name><surname>Ksiazek</surname><given-names>A</given-names></name>
</person-group>. <article-title>Angiotensin II type 1 receptor gene polymorphism in end-stage renal disease</article-title>. <source>Nephron</source> <year>2000</year>; <volume>92</volume>: <fpage>51</fpage>–<lpage>55</lpage>.</citation>
</ref>
<ref id="bibr35-1470320311430989">
<label>35.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Tarnow</surname><given-names>L</given-names></name>
<name><surname>Cambien</surname><given-names>F</given-names></name>
<name><surname>Rossing</surname><given-names>P</given-names></name>
<name><surname>Nielsen</surname><given-names>FS</given-names></name>
<name><surname>Hansen</surname><given-names>BV</given-names></name>
<name><surname>Ricard</surname><given-names>S</given-names></name><etal/>
</person-group>. <article-title>Angiotensin-II type 1 receptor gene polymorphism and diabetic microangiopathy</article-title>. <source>Nephrol Dial Transplant</source> <year>1996</year>; <volume>11</volume>: <fpage>1019</fpage>–<lpage>1023</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>